Chemical Control over Immune Recognition: A Class of Antibody-Recruiting Small Molecules That Target Prostate Cancer

Citations Over TimeTop 10% of 2009 papers

Abstract

Prostate cancer is the second leading cause of cancer-related death among the American male population, and society is in dire need of new approaches to treat this disease. Here we report the design, synthesis, and biological evaluation of a class of bifunctional small molecules called antibody-recruiting molecules targeting prostate cancer (ARM-Ps) that enhance the recognition of prostate cancer cells by the human immune system. ARM-P derivatives were designed rationally via the computational analysis of crystallographic data, and we demonstrate here that these materials are able to (1) bind prostate-specific membrane antigen (PSMA) with high affinity (high pM to low nM), (2) template the formation of ternary complexes of anti-DNP antibodies, ARM-P, and LNCaP human prostate cancer cells, and (3) mediate the antibody-dependent killing of LNCaP cells in the presence of human effector cells. This manuscript describes the application of fundamental chemical principles to the design of a novel class of molecules with high therapeutic potential. We believe that this general small-molecule-based strategy could give rise to novel directions in treating cancer and other diseases.

Related Papers

• → Characterization of a novel metastatic prostate cancer cell line of LNCaP origin(2015)28 cited
• → Use of a hormone-sensitive (LNCaP) and a hormone-resistant (LNCaP-r) cell line in prostate cancer research(1997)20 cited
• Inhibitive effect of androgen receptor antisense RNA on tumorigenesis of human prostate cancer cell LNCaP(2003)
• Effects of α-Anordrin on the Growth of Androgen-Dependent Human Prostate Cancer Cell Line LNCaP(2008)
• Establishment of androgen-independent human prostate cancer cell line model LNCaP-AI(2008)